HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.
Mr Zimdars is currently Executive Board Member of HAEMATO AG and Supervisory Board Member of M1 Kliniken AG. Due to the takeover of shares in HAEMATO AG by M1 Kliniken AG as of July 1, 2020, it is not possible to excercise both functions in parallel. Mr Zimdars chose the function of Supervisory Board Member at M1 Kliniken AG in order to be able to support both companies in the future.
The Supervisory Board of HAEMATO AG would like to thank Mr Zimdars for his successful engagement and the good cooperation.
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.
HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share: Subscribed capital: EUR 22,867,154 Listed class of shares: bearer ordinary shares ISIN: DE000619070 WKN: 619070 Stock exchange code: HAEContact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 firstname.lastname@example.org
25-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld
Germany Phone: +49 (0)30 897 30 86 70 Fax: +49 (0)30 897 30 86 79 E-mail: email@example.com Internet: www.haemato.ag ISIN: DE0006190705 WKN: 619070 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 1079449 End of Announcement DGAP News Service
1079449 25-Jun-2020 CET/CEST